Clinical Trial Update: Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial of DS-8273a in combination with nivolumab for advanced colorectal cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• DS-8273a
• nivolumab (nivolumab)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Colorectal Neoplasm | Phase 1 | Status: TERMINATED